NASDAQ:PRFX • IL0011651580
The current stock price of PRFX is 3.34 USD. In the past month the price decreased by -29.35%. In the past year, price decreased by -78.86%.
ChartMill assigns a fundamental rating of 2 / 10 to PRFX. The financial health of PRFX is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PRFX reported a non-GAAP Earnings per Share(EPS) of -160.82. The EPS increased by 81.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.69% | ||
| ROE | -172.78% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.49 | 964.817B | ||
| JNJ | JOHNSON & JOHNSON | 21.19 | 590.254B | ||
| MRK | MERCK & CO. INC. | 22.52 | 301.963B | ||
| PFE | PFIZER INC | 8.94 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 121.595B | ||
| ZTS | ZOETIS INC | 18.53 | 56.906B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.172B | ||
| VTRS | VIATRIS INC | 6.32 | 18.486B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.312B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.33 | 9.313B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The firm is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The firm also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
PRF TECHNOLOGIES LTD
65 Yigal Alon St.
TEL AVIV-YAFO 6745442 IL
CEO: Ilan Hadar
Employees: 2
Phone: 97237177051
PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The firm is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The firm also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
The current stock price of PRFX is 3.34 USD. The price increased by 4.37% in the last trading session.
PRFX does not pay a dividend.
PRFX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRFX.